Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms
Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), has announced the results of a scientific study on the effectiveness of cannabinoids in treating fibromyalgia (FM). The TOMAS study examined the impact of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms in patients with an average age of 52 years.
Key findings include:
- Improvements in pain scores, sleep quality, and overall quality of life
- Reduction in co-medication use
- Potential for cannabinoids as an effective and cost-efficient treatment option
The study provides valuable insights for the medical community on using cannabinoids to manage chronic pain and improve the quality of life for FM patients. Tilray Medical continues to support global medical trials studying the efficacy of medical cannabis for various indications.
Tilray Medical, una divisione di Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), ha annunciato i risultati di uno studio scientifico sull'efficacia dei cannabinoidi nel trattamento della fibromialgia (FM). Lo studio TOMAS ha esaminato l'impatto del THC18 di Tilray Flower Secco sul dolore cronico e su altri sintomi associati alla FM in pazienti con un'età media di 52 anni.
I risultati chiave includono:
- Miglioramenti nei punteggi del dolore, nella qualità del sonno e nella qualità della vita complessiva
- Riduzione nell'uso di co-medicazioni
- Potenziale dei cannabinoidi come opzione di trattamento efficace e conveniente
Lo studio fornisce preziose informazioni per la comunità medica sull'uso dei cannabinoidi per gestire il dolore cronico e migliorare la qualità della vita dei pazienti con FM. Tilray Medical continua a supportare studi clinici globali che indagano l'efficacia della cannabis medica per varie indicazioni.
Tilray Medical, una división de Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), ha anunciado los resultados de un estudio científico sobre la efectividad de los cannabinoides en el tratamiento de la fibromialgia (FM). El estudio TOMAS examinó el impacto de la flor seca THC18 de Tilray en el dolor crónico y otros síntomas asociados a la FM en pacientes con una edad promedio de 52 años.
Los hallazgos clave incluyen:
- Mejoras en los puntajes de dolor, calidad del sueño y calidad de vida general
- Reducción en el uso de co-medicaciones
- Potencial de los cannabinoides como una opción de tratamiento efectiva y rentable
El estudio proporciona información valiosa para la comunidad médica sobre el uso de cannabinoides para manejar el dolor crónico y mejorar la calidad de vida de los pacientes con FM. Tilray Medical continúa apoyando ensayos médicos globales que estudian la eficacia del cannabis médico para diversas indicaciones.
틸레이 메디컬(Tilray Medical)은 틸레이 브랜드(Tilray Brands, Inc. NASDAQ: TLRY; TSX: TLRY)의 한 부서로, 섬유근육통(FM) 치료에 있어 칸나비노이드의 효과에 대한 과학 연구 결과를 발표했습니다. TOMAS 연구는 평균 연령 52세의 환자들을 대상으로 틸레이 드라이 플라워 THC18이 만성 통증 및 FM과 관련된 기타 증상에 미치는 영향을 조사했습니다.
주요 발견은 다음과 같습니다:
- 통증 점수, 수면 질 및 전반적인 삶의 질 개선
- 공동 약물 사용 감소
- 칸나비노이드의 효과적이고 비용 효율적인 치료 옵션 잠재력
이 연구는 만성 통증 관리 및 FM 환자의 삶의 질 향상에 있어 칸나비노이드 사용에 대한 의료 커뮤니티에 귀중한 통찰력을 제공합니다. 틸레이 메디컬은 다양한 적응증에 대한 의료용 대마초의 효능을 연구하는 글로벌 의료 시험을 계속 지원하고 있습니다.
Tilray Medical, une division de Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a annoncé les résultats d'une étude scientifique sur l'efficacité des cannabinoïdes dans le traitement de la fibromyalgie (FM). L'
Les résultats clés comprennent :
- Améliorations des scores de douleur, de la qualité du sommeil et de la qualité de vie globale
- Réduction de l'utilisation de co-médicaments
- Potentiel des cannabinoïdes en tant qu'option de traitement efficace et rentable
L'étude fournit des informations précieuses pour la communauté médicale sur l'utilisation des cannabinoïdes pour gérer la douleur chronique et améliorer la qualité de vie des patients atteints de FM. Tilray Medical continue de soutenir des essais médicaux mondiaux étudiant l'efficacité du cannabis médical pour diverses indications.
Tilray Medical, eine Abteilung von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), hat die Ergebnisse einer wissenschaftlichen Studie zur Wirksamkeit von Cannabinoiden bei der Behandlung von Fibromyalgie (FM) veröffentlicht. Die TOMAS-Studie untersuchte die Auswirkungen von Tilray Trockenblüten THC18 auf chronische Schmerzen und andere mit FM zusammenhängende Symptome bei Patienten mit einem Durchschnittsalter von 52 Jahren.
Zu den wichtigsten Ergebnissen gehören:
- Verbesserungen der Schmerzwerte, der Schlafqualität und der allgemeinen Lebensqualität
- Reduzierung des Einsatzes von Begleitmedikamenten
- Potenzial der Cannabinoide als effektive und kostengünstige Behandlungsoption
Die Studie bietet wertvolle Einblicke für die medizinische Gemeinschaft zur Verwendung von Cannabinoiden zur Bewältigung von chronischen Schmerzen und zur Verbesserung der Lebensqualität von FM-Patienten. Tilray Medical unterstützt weiterhin globale medizinische Studien zur Wirksamkeit von medizinischem Cannabis bei verschiedenen Indikationen.
- Positive outcomes in pain management and other fibromyalgia-associated symptoms
- Improvements in pain scores, sleep quality, and overall quality of life for patients
- Reduction in co-medication use, suggesting potential cost-efficiency
- Advancement in understanding the therapeutic potential of cannabinoids for chronic pain
- None.
Insights
The TOMAS study presents promising results for fibromyalgia patients using Tilray's medical cannabis. Key findings include improved pain scores, sleep quality and overall quality of life. Notably, there was a
This study could have positive implications for Tilray's market position in the medical cannabis sector. By demonstrating efficacy in fibromyalgia treatment, Tilray may expand its patient base and potentially increase revenue from this product line. The reduction in co-medication use is particularly noteworthy, as it could lead to cost savings for healthcare systems, potentially making Tilray's products more attractive to payers. However, investors should be cautious as regulatory hurdles and competition in the medical cannabis market remain significant factors. The study's results may also support Tilray's efforts to expand into new markets where medical cannabis is being considered for chronic pain management.
While this study presents positive outcomes, it's important to note that regulatory landscapes for medical cannabis vary globally. Tilray's expansion and product adoption may face legal challenges in certain jurisdictions. The study's results could potentially support regulatory arguments for broader access to medical cannabis for fibromyalgia treatment. However, the legal status of medical cannabis remains complex and evolving in many countries. Tilray should be prepared to navigate varying regulatory requirements and potentially engage in advocacy efforts to support access to their products based on this and future research.
LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced a new scientific publication supported by Tilray Medical titled, Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms: A Case Series (TOMAS). The study examines the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) under the guidance of healthcare providers.
The TOMAS study, consisting of patients with an average age of 52 years, examined the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study sheds light on the impact of cannabinoids on health outcomes, with a particular focus on pain, sleep, and quality of life.
With medical cannabis guidance and supervision, the study demonstrated improvements in pain scores, sleep quality, and overall quality of life for fibromyalgia patients. Moreover, there was a notable reduction in co-medication, suggesting that cannabinoids may be an effective and cost-efficient treatment option for this population. The results of this study provide valuable insights for the medical and scientific community on the use of cannabinoids in managing chronic pain and improving the quality of life for patients with fibromyalgia.
José Tempero, Tilray’s Medical Director, commented, "The findings of this study are encouraging and provide hope for fibromyalgia patients who are seeking effective treatments. At Tilray, we are committed to conducting comprehensive scientific research that ensures our treatments are based on evidence and can improve patient care. We believe that these results represent a significant step forward in advancing the understanding of the therapeutic potential of cannabinoids and their role in managing chronic pain."
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, said, "Tilray’s involvement in this study underscores our unwavering commitment to advancing medical research and unlocking the full therapeutic potential of medical cannabis. The TOMAS study and its positive outcomes for patients with fibromyalgia, highlights the potential of cannabinoids as a safe and effective treatment option for patients with chronic pain and associated symptoms. Tilray Medical remains committed to advancing the science of medical cannabis and empowering patients and healthcare practitioners with the knowledge they need to make informed decisions about their health."
Tilray Medical’s mission is to continue transforming lives and fostering dignity for patients in need through access to medical cannabis. Today, Tilray is a leading provider of EU-GMP certified medical cannabis products in over 20 countries with a comprehensive portfolio of THC and CBD products. Tilray has supported medical trials globally, across Europe, Canada, the United States, Australia, and Latin America, studying the efficacy of medical cannabis as a treatment for indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder, and alcohol use disorders.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Contacts:
Tilray Brands: news@tilray.com
Investors: investors@tilray.com
FAQ
What were the main findings of the TOMAS study supported by Tilray Medical (TLRY)?
How does the TOMAS study impact Tilray's (TLRY) position in the medical cannabis market?
What is the average age of patients in the TOMAS study conducted by Tilray (TLRY)?
In how many countries does Tilray Medical (TLRY) provide EU-GMP certified medical cannabis products?
